Anavex Life Sciences Corp. AVXL

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001314052


None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $103.8M
Warnings	late filer, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Aug 28, 2026 72 days before the rescan; latest periodic filing 10-Q received Aug 28, 2026
Last close	$1.15 2026-11-06; market equity $106.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Nov 25, 2025

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS") diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 57.9						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

one or more required annual facts are missing						
Accruals ratio	(6.1%)	(6.6%)		57.9	802	2025-09-30
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	not computable	(0.37)				
required facts have no common fiscal period end						
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	not computable	2.94x				
latest aligned inputs end 2019-09-30; latest annual assets end 2025-09-30						
Growth and financing, sleeve percentile 58.8						
Revenue growth, three-year compound	not computable	10.0%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(12.1%)	2.2%		71.9	696	2025-09-30
Net share issuance, one year	5.3%	2.5%		45.6	630	2025-11-24

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(74.7%)	(2.1%)	7
Distance from 52-week high	(84.5%)	(30.5%)	7
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	1.05	0.29	87
Sales to price	not computable	0.30	
Composite equity issuance, five years	32.5%	21.4%	59
Relative strength against the sector, log excess return	(1.54)	(0.19)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-09-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$118.3M
Operating cash flow, four quarters	-$29.3M
Months of runway	48.5
Days since last periodic filing	72 (10-Q received Aug 28, 2026)
Median daily dollar volume, 63 sessions	$1.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$46.4M	2025-09-30	2026-08-28	10-K/A	26-001164
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$39.0M	2025-09-30	2026-08-28	10-K/A	26-001164
3	assets	us-gaap:Assets	$103.8M	2025-09-30	2026-08-28	10-K/A	26-001164
4	assets	us-gaap:Assets	$135.6M	2024-09-30	2026-08-28	10-K/A	26-001164
5	operating income	us-gaap:OperatingIncomeLoss	-$3.0M	2014-09-30	2014-12-29	10-K	14-007294
6	interest expense	us-gaap:InterestExpense	$7,089	2014-09-30	2015-12-29	10-K	15-003756
7	current assets	us-gaap:AssetsCurrent	$25.3M	2019-09-30	2019-12-16	10-K	19-000784
8	current liabilities	us-gaap:LiabilitiesCurrent	$5.0M	2019-09-30	2019-12-16	10-K	19-000784
9	assets	us-gaap:Assets	$154.4M	2023-09-30	2024-12-23	10-K	24-002041
10	assets	us-gaap:Assets	$152.7M	2022-09-30	2023-11-27	10-K	23-002197
11	shares outstanding	dei:EntityCommonStockSharesOutstanding	89,348,107	2025-11-24	2026-08-28	10-K/A	26-001164
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	84,815,517	2024-12-23	2024-12-23	10-K	24-002041

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.